Paclitaxel, gemcitabine, and cisplatin in non-resectable non-small-cell lung cancer

Annals of Oncology

Volumn 10, Issue 9, 1999, Pages 1043-1049

  Sorensen J B ^a   Stenbygaard, L E ^b   Dombernowsky, P ^b   Hansen, H H ^a  

^a FINSEN LABORATORY   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Chemotherapy; Non small cell lung cancer; NSCLC; Three drugs combination

Indexed keywords

CISPLATIN; GEMCITABINE; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; FEVER; HUMAN; INOPERABLE CANCER; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MALE; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEPTICEMIA; THROMBOCYTOPENIA; VOMITING;

EID: 0032841678     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008352900990     Document Type: Article

References (43)

1. Non-Small-Cell Lung Cancer Collaborative Group. Chemotherapy in non-small-cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 1995; 7: 899-909.
2. Lilenbaum RC, Langenberg P, Dickersin K. Single-agent versus combination chemotherapy in patients with advanced non-small-cell lung carcinoma: A meta-analysis of response, toxicity and survival. Cancer 1998; 82: 116-26.
3. Cullen MH. The MIC regimen in non-small-cell lung cancer. Lung Cancer 1993; 9 (Suppl 2): 81-9.
4. Hardy JR, Noble T, Smith IE. Symptom relief with moderate dose chemotherapy (mitomycin C, vinblastine, and cisplatin) in advanced non-small-cell lung cancer: Br J Cancer 1989; 60: 764-6.
5. Chang AY, Kin K, Glick J et al. Phase II study of Taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group results. J Natl Cancer Inst 1993; 85: 388-94.
6. Murphy WK, Fosella FV, Winn RJ et al. Phase II study of Taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 1993; 85: 384-8.
7. Rowinsky EK, Gilbert MR, McGuire WP et al. Sequences of Taxol and cisplatin: A phase I and pharmacologic study. J Clin Oncol 1991; 9: 1692-703.
8. Hainsworth JD, Thomson DS, Greco F. Paclitaxel by one-hour infusion: An active drug in metastatic non-small-cell lung cancer. J Clin Oncol 1995; 13: 1609-14.
9. Alberola V, Rosell R, Gonzalez-Larriba JL et al. Single-agent Taxol, three-hour infusion, in untreated advanced non-small-cell lung cancer. Ann Oncol 1995; 6 (Suppl 3): 49-52.
10. Sørensen JB, Wedervang K, Dombernowsky P. Preliminary results of a phase II study of paclitaxel and cisplatin in patients with non-small-cell lung cancer. Semin Oncol 1997; 24 (Suppl 12): 18-20.
11. Von Pawel J, Wagner H, Niederle N et al. Paclitaxel and cisplatin in patients with non-small-cell lung cancer: Results of a phase II trial. Semin Oncol 1996; 23: 7-9.
12. Giaccone G, Splinter TAW, Debruyne C et al. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. J Clin Oncol 1998; 16: 2133-41.
13. Rowinsky EK, Chaudhry V, Forastiere AA et al. Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor. Neuromuscular toxicity is dose-limiting. J Clin Oncol 1993; 11: 2010-20.
14. Klastersky J, Sculier JP. Dose-finding study of paclitaxel (Taxol) plus cisplatin in patients with non-small-cell lung cancer. Lung Cancer 1995; 12 (Suppl 2): S117-25.
15. Bonomi P, Kim K, Chang A et al. Phase III trial comparing etoposide (E) cisplatin (C) versus Taxol (T) with cisplatin - G-CSF (G) versus Taxol-cisplatin in advanced non-small-cell lung cancer. An Eastern Cooperative Oncology Group (ECOG) trial. Proc Am Soc Clin Oncol 1996; 15: 382.
16. Plunkett W, Huang P, Xu YZ et al. Gemcitabine: Metabolism, mechanisms of action, and self-potentiation. Semin Oncol 1995; 22: 3-10.
17. Hansen HH, Sørensen JB. Efficacy of single-agent gemcitabine in advanced non-small-cell lung cancer: A review. Semin Oncol 1997; 24 (Suppl 7): 38-41.
18. World Health Organization. Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 42. Geneva: WHO 1979.
19. Gehan EA. The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Dis 1961; 13: 346-53.
20. Ricci S, Antonuzzo, Galli L et al. Multicentre randomized phase II study with gemcitabine (GEM) plus cisplatin (CDDP) in patients with stage IIIB-IV NSCLC. Ann Oncol 1998; 9 (Suppl 4): 95.
21. Steward WP, Dunlop DJ, Dabuis G et al. Phase I-II study of gemcitabine and cisplatin in the treatment of advanced non-small-cell lung cancer: Preliminary results. Semin Oncol 1996; 23: 43-7.
22. Abratt RP, Bezwoda WR, Goedhals L et al. Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small-cell lung cancer. J Clin Oncol 1997; 15: 744-9.
23. Crinó L, Scagliotti G, Marangolo M et al. Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: A phase II study. J Clin Oncol 1997; 15: 297-303.
24. Einhorn L. Phase II trial of gemcitabine plus cisplatin in non-small cell lung cancer: A Hoosier Oncology Group study. Semin Oncol 1997; 24 (Suppl 8): 24-6.
25. Scagliotti G, Crino L, Conte PF et al. Randomized phase III study of gemcitabine-cisplatin versus mitomycin-ifosfamid-cisplatin in advanced non-small-cell lung cancer (NSCLC). Ann Oncol 1998; 9 (Suppl 4): 85.
26. Martinez del Prado P, Alvarez E, Alija V. Chemotherapy for stages IIIB-IV non-small-cell lung cancer. GEM-CDDP regimen: A single institution experience. Ann Oncol 1998; 9 (Suppl 4): 102.
27. Vazquez F, Baron FJ, Cueva JF et al. A cisplatin-gemcitabine phase II trial in locally advanced and advanced non-small-cell lung cancer. Ann Oncol 1998; 9 (Suppl 4): 102.
28. Orlandi-Jorquera L, Orlandi, F, Galaz P et al. Gemcitabine plus cisplatin in advanced non-small-cell lung cancer (NSCLC): A phase II study. Ann Oncol 1998; 9 (Suppl 4): 101.
29. Pesek M, Eliasova B, Certikova G. Gemcitabine and cisplatin as a first line therapy in non-small-cell lung cancer: Preliminary Czech experience. Ann Oncol 1998; 9 (Suppl 4): 96.
30. Sandler A, Denham C, von Pawel J et al. Significantly higher survival with gemcitabine-cisplatin vs. cisplatin in advanced non-small-cell lung cancer (NSCLC): Final results from an international randomized phase III study. Ann Oncol 1998; 9 (Suppl 4): 85.
31. van Zandwijk N, Crino L, Kramer GW et al. Phase II study of gemcitabine (GEM) plus cisplatin (CIS) as induction regimen for patients with stage IIIA non-small-cell lung cancer (NSCLC) by the EORTC lung cancer cooperative group (EORTC 08955). Proc Am Soc Clin Oncol 1998; 17: 468a.
32. Casal J, Huidobro G, Grane C. Gemcitabine plus cisplatin in advanced non-small-cell lung cancer. Ann Oncol 1998; 9 (Suppl 4): 103.
33. Antón A, Artal A, Carratoo A et al. Gemcitabine plus cisplatin in advanced NSCLC: Final phase II results. Proc Am Soc Clin Oncol 1997; 16: 461.
34. Shepherd FA, Cormier Y, Burkes R et al. Phase II trial of gemcitabine and weekly cisplatin for advanced non-small-cell lung cancer. Semin Oncol 1997; 24 (Suppl 8): 27-30.
35. Rinaldi M, Crino L, Scagliotti G et al. A new schedule of gemcitabine-cisplatin in advanced non-small-cell lung cancer (NSCLC) with two different cisplatin dose levels: A phase II randomized trial. Proc Am Soc Clin Oncol 1998; 17: 470a.
36. Bretti S, Celano A, Casario C et al. Gemcitabine and cisplatin combination regimen in locally advanced or metastatic non-small-cell lung cancer. A phase II study. Proc Am Soc Clin Oncol 1998; 17: 478a.
37. Gonzalez-Martin A, Garcia-Lopez JL, Crespo C et al. A phase II study of a modified cisplatin and gemcitabine regimen in advanced non-small-cell lung cancer (NSCLC): An ongoing study. Ann Oncol 1998; 9 (Suppl 4): 98.
38. Lippe P, Tummarello D, Monterubbianesi MC et al. Weekly gemcitabine (GEM) and cisplatin (PL) in advanced non-small-cell lung cancer (NSCLC): A phase II study. Proc Am Soc Clin Oncol 1998; 17: 494a.
39. Cardenal F, Rosell R, Antón A et al. Gemcitabine plus cisplatin versus etoposide in advanced non-small-cell lung cancer patients: Preliminary randomized phase III results. Proc Am Assoc Clin Oncol 1997; 16: 458.
40. Domine M, Casado V, Robles L et al. Phase II study of cisplatin-gemcitabine (C-G) for advanced non-small-cell lung cancer (NSCLC): Increasing dose-intensity and dose-density. Ann Oncol 1998; 9 (Suppl 4): 90.
41. Garcia-Gomez R, Lopez-Criado P, Guevara S et al. Gemcitabine and cisplatin in advanced non-small-cell lung cancer (NSCLC). Ann Oncol 1998; 9 (Suppl 4): 93.
42. Cartei G, Sacco C, Cioschi B et al. Gemcitabine (G) and platin (P) in advanced non-small-cell lung cancer (NSCLC): A phase II study with emphasis on intention-to-treat analysis. Proc Am Soc Clin Oncol 1998; 17: 467a.
43. Comella P, Frasci G, Panza N. Cisplatin, gemcitabine and paclitaxel in advanced non-small-cell lung cancer. A phase I study. Ann Oncol 1998; 9 (Suppl 4): 91.